Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rubius Therapeutics, Inc. - Common Stock (NQ: RUBY )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Mar 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rubius Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
89 Biggest Movers From Friday
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
Rubius Shares Plunge After Early Data From RTX-240 Solid Tumor Trial
Rubius Therapeutics Inc (NASDAQ: RUBY) has  
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Travere Therapeutics (NASDAQ:TVTX) stock increased by 16.5% to $28.87 during Friday's after-market session. The market value of their outstanding shares is at $1.8 billion. 
Via Benzinga
Will Another Enlivex Innovation Break The Glass Ceiling For Solid Tumor Treatments?
Cell therapy — the use of stem cells and various engineered immune cells to target difficult-to-treat diseases like cancer and autoimmune conditions — has arguably been one of the big breakthroughs in... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
91 Biggest Movers From Friday
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto. 
Via Benzinga
83 Biggest Movers From Yesterday
Gainers Symbotic Inc. (NASDAQ: SYM) shares surged 120.6% to settle at $20.07 on Wednesday. Symbotic reported the completion of its business combination with SVF Investment Corp. to become a publicly... 
Via Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers HeartCore Enterprises, Inc. (NASDAQ: HTCR) shares gained 81% to $1.8503 after the company authorized a $3.5 million buyback. 
Via Benzinga
What 6 Analyst Ratings Have To Say About Rubius Therapeutics
Over the past 3 months, 6 analysts have published their opinion on Rubius Therapeutics (NASDAQ:RUBY) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
69 Biggest Movers From Friday
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 123 stocks made new 52-week lows. 
Via Benzinga
Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million. 
Via Benzinga
60 Biggest Movers From Yesterday
Gainers Nkarta, Inc. (NASDAQ: NKTX) shares climbed 140.9% to close at $18.72 on Monday after the company announced Phase 1 data from independent dose finding studies of its two... 
Via Benzinga
3 Stocks Under $3 Insiders Are Aggressively Buying
US crude oil futures traded lower on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
60 Biggest Movers From Yesterday
Gainers Cyngn Inc. (NASDAQ: CYN) shares jumped 96.3% to close at $2.12 on Thursday after the company announced the official launch of DriveMod Kit, a turnkey autonomous vehicle... 
Via Benzinga
Expert Ratings for Rubius Therapeutics
Over the past 3 months, 5 analysts have published their opinion on Rubius Therapeutics (NASDAQ:RUBY) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 236 companies hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new... 
Via Benzinga
SVB Leerink Maintains Market Perform Rating for Rubius Therapeutics, Lowers Price Target To $3
SVB Leerink has decided to maintain its Market Perform rating of Rubius Therapeutics (NASDAQ:RUBY) and lower its price target from $5.00 to $3.00. Shares of Rubius Therapeutics are trading down 24.14%... 
Via Benzinga
Guggenheim Maintains Buy Rating for Rubius Therapeutics, Lowers Price Target To $5
Guggenheim has decided to maintain its Buy rating of Rubius Therapeutics (NASDAQ:RUBY) and lower its price target from $25.00 to $5.00. Shares of Rubius Therapeutics are trading down 24.14% over the... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Phio Pharma (NASDAQ:PHIO) shares increased by 46.7% to $1.33 during Friday's regular session. As of 13:31 EST, Phio Pharma's stock is trading at a volume... 
Via Benzinga
28 Stocks Moving In Friday's Mid-Day Session
Gainers Lyra Therapeutics, Inc. (NASDAQ: LYRA) shares climbed 33.3% to $5.78 as the company reported a private placement for gross proceeds of $110.5 million. TSR, Inc. (NASDAQ... 
Via Benzinga
87 Biggest Movers From Yesterday
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares jumped 150% to close at $3.80 on Wednesday. Sunshine Biopharma, last month, priced its 1.88 million unit uplisting to... 
Via Benzinga
Recap: Rubius Therapeutics Q4 Earnings
Rubius Therapeutics (NASDAQ:RUBY) reported its Q4 earnings results on Friday, February 25, 2022 at 08:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Earnings Scheduled For February 25, 2022
Companies Reporting Before The Bell • ACM Research (NASDAQ:ACMR) is estimated to report quarterly earnings at $0.64 per share on revenue of $89.53 million. •... 
Via Benzinga
Rubius Therapeutics Earnings Preview
Rubius Therapeutics (NASDAQ:RUBY) is set to give its latest quarterly earnings report on Friday, 2022-02-25. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.